Renovis Cuts Workforce By 40 Percent To Focus On Preclinical Compounds
Eliminations follow Phase III failure of an acute ischemic stroke candidate that had been in development with AstraZeneca.
Eliminations follow Phase III failure of an acute ischemic stroke candidate that had been in development with AstraZeneca.